Table 3.

Current drug-specific reversal strategies and novel agents under development

DrugDrug-specific reversal strategyAgents likely to be available in the future
Vitamin K antagonistsVitamin K, four-factor PCC
Unfractionated heparinProtamine sulphateCiraparantag
Low molecular weight heparinProtamine sulphateAndexanet alfa, Ciraparantag
FondaparinuxConsider recombinant activated factor VIIAndexanet alfa, Ciraparantag
Factor Xa inhibitorsFour-factor PCCAndexanet alfa, Ciraparantag
  • PCC = prothrombin complex concentrate